Table 1.
TCR Vβ8-specific CD8+ CTL are generated after vaccination with CD4+Vβ8+ T cells
| Exp. | CTL | Cytotoxicity for target cells, %
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 4G4 parent (Vβ−, H-2k, Qa-1b) | 4G4-6B5a (Vβ8+, H-2k, Qa-1b) | 4G4-6B5b (Vβ−, H-2k, Qa-1b) | 4G4-Vβ10 (Vβ10+, H-2k, Qa-1b) | D10 (Vβ8+, H-2k, Qa-1b) | RMA (Vβ12+, H-2b, Qa-1b) | BW-Vβ14 (Vβ14+, H-2k, Qa-1b) | BW-Vβ15 (Vβ15+, H-2k, Qa-1b) | ||
| 1 | TCV | <1 | 15.6 | <1 | <1 | 65.8 | <1 | <1 | <1 |
| 2 | TCV | <1 | 39.1 | <1 | <1 | 73.1 | <1 | <1 | <1 |
| 3 | SEB-primed | <1 | 16.5 | <1 | <1 | 34.4 | <1 | <1 | <1 |
| 4 | SEB-primed | 7.5 | 23.5 | <1 | 5.9 | 35.9 | <1 | <1 | <1 |
In each experiment, four AKR (H-2k, Qa-1b) mice were injected intravenously with syngeneic irradiated SEB-activated CD4+Vβ8+ T cells (experiments 1 and 2) or SEB (experiments 3 and 4). CD8+ T cells were isolated 7–10 days after priming, retriggered with SEB-activated CD4+Vβ8+ T cells in vitro as described in ref. 13, and assayed for cytotoxicity after 10–14 days of culture.